Fast Facts for Board Review

Medications for Advanced Melanoma

Author and Disclosure Information

As part of our commitment to resident education, Cutis is excited to offer this monthly section with board-relevant, easy-to-review material.

This fact sheet provides a list of the current US Food and Drug Administration approved medications for treatment of metastatic melanoma, and describes their mechanism of action and any related cutaneous side effects.


 

Review the PDF of the fact sheet on medications for advanced melanoma with board-relevant material. This fact sheet provides a list of the current US Food and Drug Administration approved medications for treatment of metastatic melanoma, and describes their mechanism of action and any related cutaneous side effects.

After, test your knowledge by answering the 5 practice questions.

Practice Questions

1. Which of the following medications is considered an MEK inhibitor?

a. aldesleukin

b. dacarbazine

c. ipilimumab

d. recombinant interferon alfa-2b

e. trametinib

Pages

Recommended Reading

VIDEO: Lymphadenectomies don’t boost survival in melanoma with SLN micrometastases
MDedge Dermatology
ASCO: German trial argues against complete nodal dissection for SLN-positive melanoma
MDedge Dermatology
VIDEO: Dual immunotherapy more powerful in melanoma, but where do we go from here?
MDedge Dermatology
ASCO: Combo therapy results end reign of single-drug therapy in melanoma
MDedge Dermatology
ASCO: Precision medicine initiatives take wing
MDedge Dermatology
Annual U.S. incidence of BCC pegged at 2 million
MDedge Dermatology
Coffee Each Day Keeps the Melanoma Away
MDedge Dermatology
Fake Melanoma and Nonmelanoma Skin Cancer “Cures”
MDedge Dermatology
Black Salve and Bloodroot Extract in Dermatologic Conditions
MDedge Dermatology
Prevalence and Impact of Health-Related Internet and Smartphone Use Among Dermatology Patients
MDedge Dermatology

Related Articles